Articles From: Alimera Sciences Provides Details On FDA Approval Of ILUVIEN® As The First Long-Term Treatment For Diabetic Macular Edema to All Three Leading Proxy Advisory Firms - ISS, Glass, Lewis and Egan-Jones - Recommend That Superior Industries Shareholders Vote the WHITE Proxy Card FOR Superior’s Director Nominees


A single ILUVIEN implant provides treatment for three years Alimera will hold a conference call Wednesday, October 1, at 8:30 a.m. to discuss the approval ATLANTA , Sept.
Sign-up for Alimera Sciences Provides Details On FDA Approval Of ILUVIEN® As The First Long-Term Treatment For Diabetic Macular Edema investment picks
Growth Capital Allows Alimera to Fulfill Its Milestone Obligation Triggered by FDA Approval of ILUVIEN® ATLANTA , Sept.
Sign-up for Alimera Sciences Receives $25 Million Advance from Hercules Technology Growth Capital investment picks
Company will issue a more detailed announcement on Monday, September 29 ATLANTA , Sept.
Sign-up for Alimera Sciences Receives FDA Approval For ILUVIEN®, The First Long-Term Treatment For Diabetic Macular Edema investment picks
ILUVIEN® Injections Increased over 25% in the United Kingdom on Sequential Basis from First Quarter 2014 Alimera Will Host a Conference Call at 4:30 PM ET Today ATLANTA , Aug.
Sign-up for Alimera Sciences Reports Second Quarter 2014 Financial Results investment picks
CEO to Discuss Milestone FDA Approval of ILUVIEN as the First Long-Term Treatment for Diabetic Macular Edema ATLANTA , Oct.
Sign-up for Alimera Sciences to Present at Ophthalmology Innovation Summit at the American Academy of Ophthalmology Annual Meeting investment picks
ATLANTA , July 31, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Danish Health and Medicines Authority has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
Sign-up for Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Denmark For The Treatment Of Chronic Diabetic Macular Edema investment picks
Portugal approves reimbursement for ILUVIEN ATLANTA , July 28, 2014 /PRNewswire/ -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the Norwegian Medicines Evaluation Board has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered insufficiently responsive to available therapies.
Sign-up for Alimera Sciences' ILUVIEN® Receives Marketing Authorization In Norway For The Treatment Of Chronic Diabetic Macular Edema investment picks
Sweden is latest country to grant marketing authorization ATLANTA , Sept.
Sign-up for Alimera Sciences' ILUVIEN® Receives Tenth National Marketing Authorization For The Treatment Of Chronic Diabetic Macular Edema investment picks
2014/10/16
BEIJING--Chinese e-commerce giant Alibaba Group Holding Ltd.'s financial services affiliate said Thursday that Alipay Wallet, the mobile application version of its electronic payment service, now has 190 million active users.
Sign-up for Alipay Wallet Hits 190 Million Active Users investment picks
2014/10/17
LIVONIA, Mich.
Sign-up for Alison Davis-Blake Elected to Tower International Board of Directors investment picks
http://media.marketwire.com/attachments/201307/170375_AWC-logo-small.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1133331&ProfileId=051205&sourceType=1 SCOTTSDALE, AZ --
Sign-up for Alkaline Water Co. Begins Outdoor Ad Campaign in Southern California investment picks
http://media.marketwire.com/attachments/201307/170375_AWC-logo-small.jpg http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1143873&ProfileId=051205&sourceType=1 SCOTTSDALE, AZ --
Sign-up for Alkaline Water Co. Now at Select Whole Foods Markets in Arizona investment picks
SCOTTSDALE, Ariz., July 24, 2014 (GLOBE NEWSWIRE) -- The Alkaline Water Company Inc. (OTCBB:WTER) (the "Company"), developers of an innovative state of the art proprietary electrolysis beverage process, packaged and sold in 3 liter and 1 gallon sizes under the trade name Alkaline88, announced today another success for its ongoing national expansion program with acceptance for placement at FoodMaxx Supermarkets ( www.foodmaxx.com ). FoodMaxx is a 45 store warehouse market concept owned by Save Mart Supermarkets.
Sign-up for Alkaline Water Co. Products Now Available at FoodMaxx Maximum Discount Supermarkets investment picks
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=1135051&ProfileId=051205&sourceType=1 LAS VEGAS, NV --
Sign-up for Alkame Water 20 Oz. Bottle Now Available Nationwide Direct-to-Consumer Through Amazon.com With Free Shipping investment picks
Alkermes plc (NASDAQ: ALKS) today announced completion of patient enrollment in a phase 2 study of ALKS 3831, an investigational, novel, oral, broad-spectrum atypical antipsychotic medicine in development for the treatment of schizophrenia.
Sign-up for Alkermes Announces Completion of Patient Enrollment in Phase 2 Study of ALKS 3831, a Novel, Broad-Spectrum Oral Antipsychotic investment picks
Alkermes plc (NASDAQ: ALKS) today announced the initiation of FORWARD-5, the third of three core efficacy studies planned in the pivotal clinical program for ALKS 5461, a once-daily, oral investigational medicine with a novel mechanism of action for the adjunctive treatment of major depressive disorder (MDD). The study will evaluate the efficacy and safety of ALKS 5461 in patients suffering from MDD who have had an inadequate response to commonly prescribed drugs for depression, including selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine reuptake inhibitors (SNRIs). Approximately two-thirds of patients who are diagnosed with MDD do not adequately respond to initial antidepressant therapy.
Sign-up for Alkermes Announces Initiation of FORWARD-5 Clinical Study of ALKS 5461 For Treatment of Major Depressive Disorder investment picks
Alkermes plc (NASDAQ: ALKS) today announced the initiation of a phase 1 clinical study of ALKS 7106, a proprietary, novel, oral, small-molecule drug candidate for the treatment of pain.
Sign-up for Alkermes Announces Initiation of Phase 1 Clinical Study of ALKS 7106 for Treatment of Pain investment picks
Alkermes plc (NASDAQ: ALKS) today reported financial results for the second quarter of 2014.
Sign-up for Alkermes plc Reports Second Quarter 2014 Financial Results investment picks
Alkermes plc (NASDAQ: ALKS) today announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of aripiprazole lauroxil, the company’s investigational, novel, once-monthly, long-acting injectable atypical antipsychotic for the treatment of schizophrenia.
Sign-up for Alkermes Submits New Drug Application to FDA for Aripiprazole Lauroxil for Treatment of Schizophrenia investment picks
Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EDT (1:30 p.m. BST) on Thursday, July 31, 2014, to discuss the company’s financial results for the second quarter of 2014.
Sign-up for Alkermes to Host Conference Call to Discuss Second Quarter 2014 Financial Results investment picks
Alkermes plc (NASDAQ: ALKS) will host a conference call at 8:30 a.m. EDT (12:30 p.m. GMT) on Wednesday, Oct.
Sign-up for Alkermes to Host Conference Call to Discuss Third Quarter 2014 Financial Results investment picks
Alkermes plc (NASDAQ: ALKS) announced today that its corporate presentation will be webcast live at the Morgan Stanley Global Healthcare Conference on Monday, Sept.
Sign-up for Alkermes’ Corporate Presentation to be Webcast at the Morgan Stanley Global Healthcare Conference investment picks
Alkermes plc (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application (NDA) for aripiprazole lauroxil, the company’s investigational, novel, once-monthly injectable atypical antipsychotic for the treatment of schizophrenia.
Sign-up for Alkermes’ New Drug Application for Aripiprazole Lauroxil for Treatment of Schizophrenia Accepted for Filing by U.S. FDA investment picks
(NASDAQ: AMZN)—Amazon today announced all 10 episodes of the critically-acclaimed dark comedy series Transparent are now available for Prime Instant Video customers in the US, UK and Germany.
Sign-up for All 10 Episodes of the Critically Acclaimed Dark Comedy Series Transparent Are Now Available on Amazon Prime Instant Video in the US, UK and Germany investment picks
2014/9/11
Today it was announced that Siemens has been selected to build the locomotives and passenger coaches for the All Aboard Florida passenger rail project that will connect South and Central Florida.
Sign-up for All Aboard Florida Selects Siemens as Train Manufacturer investment picks
2014/9/16
http://at.marketwire.com/accesstracking/AccessTrackingLogServlet?PrId=11G021881-001&sourceType=1 http://www.marketwire.com/library/MwGo/2014/9/16/11G021881/87a481fe7b41ab6b_org-638840709.jpg ST.
Sign-up for All Children's Hospital Johns Hopkins Medicine Continues Fight Against Childhood Obesity With Grant From Kohl's Department Stores investment picks
2014/10/2
By Jennifer Booton, MarketWatch NEW YORK (MarketWatch)--The retail world is coming upon its most lucrative time of the year: the holiday season.
Sign-up for All I want for Christmas is a...drone? investment picks
Teva Pharmaceutical Industries Ltd.
Sign-up for All Proposals Approved at Teva's Annual Meeting of Shareholders investment picks
2014/10/14
By Shawn Langlois, MarketWatch So this is how it feels when the S&P 500 (SPX) breaks below its 200 day-moving average.
Sign-up for All the reasons to sell this market are enough to draw a guy in investment picks
Superior Industries International, Inc. (NYSE:SUP), the largest manufacturer of aluminum wheels for passenger cars and light-duty vehicles in North America, today announced that the three leading independent proxy advisory firms—ISS Proxy Advisory Services, Glass, Lewis & Co., and Egan-Jones—each have recommended that Superior shareholders vote the WHITE proxy card FOR all four of Superior’s director nominees at the Company’s 2014 Annual Meeting of Shareholders, to be held on August 15, 2014.
Sign-up for All Three Leading Proxy Advisory Firms - ISS, Glass, Lewis and Egan-Jones - Recommend That Superior Industries Shareholders Vote the WHITE Proxy Card FOR Superior’s Director Nominees investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Alimera Sciences Provides Details On FDA Approval Of ILUVIEN® As The First Long-Term Treatment For Diabetic Macular Edema to All Three Leading Proxy Advisory Firms - ISS, Glass, Lewis and Egan-Jones - Recommend That Superior Industries Shareholders Vote the WHITE Proxy Card FOR Superior’s Director Nominees
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices